Results 31 to 40 of about 23,706 (182)

Use of Continuous Renal Replacement Therapy for Removal of Dabigatran in a Patient in Need of Emergent Surgery

Case Reports in Critical Care, 2016
Purpose. To report the ability to remove serum dabigatran using continuous renal replacement therapy (CRRT) in a patient with life-threatening bleeding. Summary.
Sara E. Parli, Melissa L. Thompson Bastin, Daniel A. Lewis   +2 more
doaj   +1 more source

New indications for dabigatran: A suggestion from a drug use evaluation study

Journal of Research in Pharmacy Practice, 2017
Objective: Dabigatran etexilate is a novel oral anticoagulant with several advantages over warfarin such as no need for routine monitoring and fewer drug interactions. This drug was added to our hospital's formulary in 2012.
Farzaneh Ashrafi, Najmeh Rezaie, Sarah Mousavi   +2 more
doaj   +1 more source

Difficult reversal of dabigatran with idarucizumab in a multiple-trauma patient: A question of dose?

Trauma Case Reports, 2021
Dabigatran is an oral anticoagulant directly acting as thrombin inhibitor. The monoclonal antibody idarucizumab was developed to reverse its anticoagulatory effects after application of a standardized dose.
Mathias Ströhle, Christopher Rugg, Stefan Schmid, Dietmar Fries, Elgar Oswald   +4 more
doaj   +1 more source

Volume replacement strategies do not impair the binding of dabigatran to idarucizumab: Porcine model of hemodilution.

PLoS ONE, 2019
BackgroundIdarucizumab is a humanized Fab fragment that specifically reverses dabigatran anticoagulation. In trauma, volume expanders are used for resuscitation to compensate for blood loss and hemorrhagic shock, but it is unknown whether volume ...
Oliver Grottke, Joanne van Ryn, Christian Zentai, Guanfa Gan, Markus Honickel, Rolf Rossaint, Hugo Ten Cate, Henri M H Spronk   +7 more
doaj   +1 more source

Comparison of benefit between dabigatran and warfarin among patients with atrial fibrillation: A systematic review

Archives of Pharmacy Practice, 2016
Warfarin is recognized as the standard antithrombotic agent for stroke prevention. However, new oral anticoagulant such as dabigatran constitutes huge improvement to compensate for the limitation of warfarin.
Amal K Sulieman
doaj   +1 more source

Determination of Dabigatran Concentration in Human Plasma and Breast Milk

International Journal of Analytical Chemistry, 2021
Venous thromboembolism (VTE) is an important cause of death following childbirth. Dabigatran etexilate can be a useful prophylaxis in susceptible women during the postpartum period. However, it is not clear whether dabigatran is excreted into breast milk
F. Sidgwick, A. Porter, P. Ayuk, F. Kamali, A. Truemann   +4 more
doaj   +1 more source

PERANAN IDARUCIZUMAB UNTUK MENETRALISIR EFEK ANTIKOAGULAN DABIGATRAN [PDF]

, 2019
Latar Belakang: Dabigatran etexilate (Pradaxa) telah disetujui oleh FDA dan Uni Eropa sebagai antikoagulan untuk mencegah stroke dan emboli sistemik pada pasien dengan atrial fibrilasi non-valvular dan satu atau lebih faktor risiko lain.
Soejitno, Andreas, Putra, Ida Bagus Kusuma   +1 more
core   +1 more source

Dabigatran Level Before Reversal Can Predict Hemostatic Effectiveness of Idarucizumab in a Real-World Setting

Frontiers in Medicine, 2020
Background: Idarucizumab has been included in guidelines for the management of bleeding or surgical procedure in dabigatran-treated patients without need for biological monitoring.
Nicolas Gendron, Nicolas Gendron, Richard Chocron, Richard Chocron, Paul Billoir, Julien Brunier, Laurence Camoin-Jau, Marie Tuffigo, Dorothée Faille, Dorothée Faille, Dorian Teissandier, Juliette Gay, Juliette Gay, Emmanuelle de Raucourt, Emmanuelle de Raucourt, Ludovic Suner, Corentin Bonnet, Anne-Céline Martin, Anne-Céline Martin, Dominique Lasne, Chayma Ladhari, Aurélien Lebreton, Laurent Bertoletti, Laurent Bertoletti, Nadine Ajzenberg, Nadine Ajzenberg, Pascale Gaussem, Pascale Gaussem, Pierre-Emmanuel Morange, Pierre-Emmanuel Morange, Pierre-Emmanuel Morange, Véronique Le Cam Duchez, Alain Viallon, Pierre-Marie Roy, Pierre-Marie Roy, Agnès Lillo-le Louët, Agnès Lillo-le Louët, David M. Smadja, David M. Smadja, David M. Smadja   +39 more
doaj   +1 more source

Extended use of dabigatran, warfarin, or placebo in venous thromboembolism [PDF]

, 2013
BACKGROUND: Dabigatran, which is administered in a fixed dose and does not require laboratory monitoring, may be suitable for extended treatment of venous thromboembolism.
Schellong, S, Kvamme, AM, Mismetti, P, Eriksson, H, Friedman, J, DI MINNO, GIOVANNI, Schulman, S1, Kakkar, AK, Goldhaber, SZ, Kearon, C, Goldhaber, S, Kakkar A, Schulman, S, Baanstra, D   +13 more
core   +2 more sources

Dabigatran Monitoring Was Influenced by Thrombin Time Reagent With Different Thrombin Concentrations

Clinical and Applied Thrombosis/Hemostasis, 2019
To describe the effect of dabigatran on thrombin time (TT) reagents at different concentrations of thrombin. Pooled normal plasma enriched with dabigatran was dissolved in dimethylsulfoxide (DMSO) at concentrations of 0, 20, 50, 100, 200, 300, and 500 ng/
Xiaoping Xu, Qian Liang
doaj   +1 more source